<DOC>
	<DOC>NCT00171769</DOC>
	<brief_summary>This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation</brief_summary>
	<brief_title>Atrial Fibrillation Feasibility Certoparin Trial - AFFECT</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Certoparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<criteria>persistent AF (electrical cardioversion is planned) written informed consent acute clinical signs of venous thromboembolism current oral anticoagulation indication for medical cardioversion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>